Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

Summary

An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis

Timeline

Start

2016-07-11

Primary completion

2017-09-20

Completion

2018-01-02

Drugs

Indications